Indications
Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.
Composition
- Active substance
- daclizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zenapax
- Active substance
- daclizumab
- ATC code
- L04AA08
- Therapeutic area
- Graft Rejection, Kidney Transplantation
- Marketing authorisation holder
- Roche Registration Ltd.